Related content

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study

By Bajetta Emilio   Catena Laura   Fazio Nicola   Pusceddu Sara   Biondani Pamela   Blanco Giusi   Ricci Sergio   Aieta Michele   Pucci Francesca   Valente Monica   Bianco Nadia   Mauri Chiara Maria   Spada Francesca  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2457-2463

Blackwell Publishing

Access to resources Recommend Favorite

Treatment Patterns, Outcomes and Costs Among Elderly Patients with Chronic Myeloid Leukaemia: A Population-Based Analysis

By Joseph Menzin  

Drugs & Aging, Vol. 21, Iss. 11, 2004-01 ,pp. : 737-746

Adis International

Access to resources Recommend Favorite

Everolimus [RAD 001], in combination with octreotide long-acting repeatable (LAR), shows promising antitumour activity

By  

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Octreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly

By Yang Lily P.H.   Keating Gillian M.  

Drugs, Vol. 70, Iss. 13, 2010-09 ,pp. : 1745-1769

Adis International

Access to resources Recommend Favorite

Octreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly

By McKeage K.   Cheer S.   Wagstaff A.J.  

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2473-2499

Adis International

Access to resources Recommend Favorite